244 related articles for article (PubMed ID: 37435833)
1. Infigratinib, a selective FGFR1-3 tyrosine kinase inhibitor, alters dentoalveolar development at high doses.
Michel ZD; Aitken SF; Glover OD; Alejandro LO; Randazzo D; Dambkowski C; Martin D; Collins MT; Somerman MJ; Chu EY
Dev Dyn; 2023 Dec; 252(12):1428-1448. PubMed ID: 37435833
[TBL] [Abstract][Full Text] [Related]
2. Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies.
Savarirayan R; De Bergua JM; Arundel P; McDevitt H; Cormier-Daire V; Saraff V; Skae M; Delgado B; Leiva-Gea A; Santos-Simarro F; Salles JP; Nicolino M; Rossi M; Kannu P; Bober MB; Phillips J; Saal H; Harmatz P; Burren C; Gotway G; Cho T; Muslimova E; Weng R; Rogoff D; Hoover-Fong J; Irving M
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221084848. PubMed ID: 35342457
[TBL] [Abstract][Full Text] [Related]
3. Low-Dose Infigratinib Increases Bone Growth And Corrects Growth Plate Abnormalities In An Achondroplasia Mouse Model.
Demuynck B; Flipo J; Kaci N; Dambkowski C; Paull M; Muslimova E; Shah BP; Legeai-Mallet L
J Bone Miner Res; 2024 Apr; ():. PubMed ID: 38590263
[TBL] [Abstract][Full Text] [Related]
4. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.
Lyou Y; Grivas P; Rosenberg JE; Hoffman-Censits J; Quinn DI; P Petrylak D; Galsky M; Vaishampayan U; De Giorgi U; Gupta S; Burris H; Rearden J; Li A; Wang H; Reyes M; Moran S; Daneshmand S; Bajorin D; Pal SK
Eur Urol; 2020 Dec; 78(6):916-924. PubMed ID: 32847703
[TBL] [Abstract][Full Text] [Related]
5. Infigratinib, a Selective Fibroblast Growth Factor Receptor Inhibitor, Suppresses Stent-Induced Tissue Hyperplasia in a Rat Esophageal Model.
Fu Y; Zhao H; Li J; Li Y; Gong T; An C; Wang R; Li X
Cardiovasc Intervent Radiol; 2023 Sep; 46(9):1267-1275. PubMed ID: 37491520
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domains.
Wang Q; Green RP; Zhao G; Ornitz DM
Development; 2001 Oct; 128(19):3867-76. PubMed ID: 11585811
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia--genetic short limbed dwarfism.
Aviezer D; Golembo M; Yayon A
Curr Drug Targets; 2003 Jul; 4(5):353-65. PubMed ID: 12816345
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.
Webster MK; Donoghue DJ
EMBO J; 1996 Feb; 15(3):520-7. PubMed ID: 8599935
[TBL] [Abstract][Full Text] [Related]
9. Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
Vlacic G; Hoda MA; Klikovits T; Sinn K; Gschwandtner E; Mohorcic K; Schelch K; Pirker C; Peter-Vörösmarty B; Brankovic J; Dome B; Laszlo V; Cufer T; Rozman A; Klepetko W; Grasl-Kraupp B; Hegedus B; Berger W; Kern I; Grusch M
Cells; 2019 Sep; 8(9):. PubMed ID: 31527449
[TBL] [Abstract][Full Text] [Related]
10. ARQ 087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3.
Balek L; Gudernova I; Vesela I; Hampl M; Oralova V; Kunova Bosakova M; Varecha M; Nemec P; Hall T; Abbadessa G; Hatch N; Buchtova M; Krejci P
Bone; 2017 Dec; 105():57-66. PubMed ID: 28826843
[TBL] [Abstract][Full Text] [Related]
11. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
Murakami S; Balmes G; McKinney S; Zhang Z; Givol D; de Crombrugghe B
Genes Dev; 2004 Feb; 18(3):290-305. PubMed ID: 14871928
[TBL] [Abstract][Full Text] [Related]
12. Chimeras of the native form or achondroplasia mutant (G375C) of human fibroblast growth factor receptor 3 induce ligand-dependent differentiation of PC12 cells.
Thompson LM; Raffioni S; Wasmuth JJ; Bradshaw RA
Mol Cell Biol; 1997 Jul; 17(7):4169-77. PubMed ID: 9199352
[TBL] [Abstract][Full Text] [Related]
13. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Lassman AB; Sepúlveda-Sánchez JM; Cloughesy TF; Gil-Gil MJ; Puduvalli VK; Raizer JJ; De Vos FYF; Wen PY; Butowski NA; Clement PMJ; Groves MD; Belda-Iniesta C; Giglio P; Soifer HS; Rowsey S; Xu C; Avogadri F; Wei G; Moran S; Roth P
Clin Cancer Res; 2022 Jun; 28(11):2270-2277. PubMed ID: 35344029
[TBL] [Abstract][Full Text] [Related]
14. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
15. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.
Colvin JS; Bohne BA; Harding GW; McEwen DG; Ornitz DM
Nat Genet; 1996 Apr; 12(4):390-7. PubMed ID: 8630492
[TBL] [Abstract][Full Text] [Related]
16. A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3.
Wang Y; Spatz MK; Kannan K; Hayk H; Avivi A; Gorivodsky M; Pines M; Yayon A; Lonai P; Givol D
Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4455-60. PubMed ID: 10200283
[TBL] [Abstract][Full Text] [Related]
17. Circulatory CNP Rescues Craniofacial Hypoplasia in Achondroplasia.
Yamanaka S; Nakao K; Koyama N; Isobe Y; Ueda Y; Kanai Y; Kondo E; Fujii T; Miura M; Yasoda A; Nakao K; Bessho K
J Dent Res; 2017 Dec; 96(13):1526-1534. PubMed ID: 28644737
[TBL] [Abstract][Full Text] [Related]
18. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors.
Li C; Chen L; Iwata T; Kitagawa M; Fu XY; Deng CX
Hum Mol Genet; 1999 Jan; 8(1):35-44. PubMed ID: 9887329
[TBL] [Abstract][Full Text] [Related]
19. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.
Botrus G; Raman P; Oliver T; Bekaii-Saab T
Expert Opin Investig Drugs; 2021 Apr; 30(4):309-316. PubMed ID: 33307867
[TBL] [Abstract][Full Text] [Related]
20. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]